{"title": "Review on acceptability and WTP for HIV vaccine", "author": "Jppres", "url": "https://jppres.com/jppres/tag/immunization/", "hostname": "jppres.com", "description": null, "sitename": "Journal of Pharmacy & Pharmacognosy Research", "date": "2022-07-06", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "J. Pharm. Pharmacogn. Res., vol. 10, no. 4, pp. 748-767, July-August 2022.\nDOI:\n[https://doi.org/10.56499/jppres22.1404_10.4.748](https://doi.org/10.56499/jppres22.1404_10.4.748)\nReview\nAcceptability of and willingness to pay for human immunodeficiency virus vaccination: A systematic literature review\n[Aceptabilidad y disposici\u00f3n a pagar por la vacunaci\u00f3n contra el virus de la inmunodeficiencia humana: Una revisi\u00f3n sistem\u00e1tica de la literatura]\nTram N.T. Huyen1, Somying Pumtong1, Sermsiri Sangroongruangsri1, Luerat Anuratpanich1,2*\n1Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.\n2Department of Pharmacy, Division of Social and Administrative Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand.\n*E-mail:\n[luerat.anu@mahidol.ac.th](mailto:luerat.anu@mahidol.ac.th)\nAbstract\nContext: Vaccines for the human immunodeficiency virus (HIV) have considerably improved public health in the last century. Important considerations, however, are that effective vaccination substantially depends on the acceptability of future vaccines and that monetary measurements of vaccine preference, as reflected by the willingness to pay (WTP), may help policymakers establish health capital priorities.\nAims: To systematically pool data on vaccine acceptability and WTP.\nMethods: A systematic search was performed over five databases to identify eligible articles published from 2005 to 2020, and key terms were used in accordance with the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analyses. Two researchers independently assessed the articles, extracted relevant data, and drew numerical and descriptive summaries for result presentation via Excel.\nResults: Out of 31 eligible studies, 28 and 3 reported on the acceptability of and WTP for HIV vaccination, respectively. Acceptability levels ranged from 2.94% to 93.10%, with the average being 60.16%, and WTP values fell between US$108 and US$671. The most prevalent themes were the characteristics of HIV vaccines (safety/side effects, efficacy, duration of protection, vaccine-induced seropositivity).\nConclusions: Overall, the review uncovered a lack of standardized, universal, and acceptable scales for determining acceptability and WTP. The evaluation provided a comprehensive and systematic summary of these matters along with useful information for policymakers on maximizing public health under limited resources.\nKeywords: acceptability; HIV; immunization; systematic review; vaccination; willingness-to-pay.\nResumen\nContexto: Las vacunas contra el virus de la inmunodeficiencia humana (VIH) han mejorado considerablemente la salud p\u00fablica en el \u00faltimo siglo. Las consideraciones importantes, sin embargo, son que la vacunaci\u00f3n efectiva depende sustancialmente de la aceptabilidad de las vacunas futuras y que las mediciones monetarias de la preferencia por la vacuna, reflejadas en la disposici\u00f3n a pagar (WTP), pueden ayudar a los formuladores de pol\u00edticas a establecer prioridades de capital de salud.\nObjetivos: Agrupar sistem\u00e1ticamente los datos sobre la aceptabilidad de las vacunas y la disposici\u00f3n a pagar.\nM\u00e9todos: Se realiz\u00f3 una b\u00fasqueda sistem\u00e1tica en cinco bases de datos para identificar art\u00edculos elegibles publicados entre 2005 y 2020, y se utilizaron t\u00e9rminos clave de acuerdo con las pautas de Preferred Reporting Items for Systematic Review and Meta-Analyses. Dos investigadores evaluaron de forma independiente los art\u00edculos, extrajeron datos relevantes y elaboraron res\u00famenes num\u00e9ricos y descriptivos para la presentaci\u00f3n de resultados a trav\u00e9s de Excel.\nResultados: De los 31 estudios elegibles, 28 y 3 informaron sobre la aceptabilidad y la disposici\u00f3n a pagar por la vacunaci\u00f3n contra el VIH, respectivamente. Los niveles de aceptabilidad oscilaron entre 2,94 % y 93,10 %, con un promedio de 60,16 %, y los valores de disposici\u00f3n a pagar estuvieron entre US$ 108 y US$ 671. Los temas m\u00e1s predominantes fueron las caracter\u00edsticas de las vacunas contra el VIH (seguridad/efectos secundarios, eficacia, duraci\u00f3n de la protecci\u00f3n, seropositividad inducida por la vacuna).\nConclusiones: En general, la revisi\u00f3n descubri\u00f3 la falta de escalas estandarizadas, universales y aceptables para determinar la aceptabilidad y la disposici\u00f3n a pagar. La evaluaci\u00f3n brind\u00f3 un resumen completo y sistem\u00e1tico de estos asuntos junto con informaci\u00f3n \u00fatil para los formuladores de pol\u00edticas sobre c\u00f3mo maximizar la salud p\u00fablica con recursos limitados.\nPalabras Clave: aceptabilidad; inmunizaci\u00f3n; revisi\u00f3n sistem\u00e1tica; vacunaci\u00f3n; VIH; voluntad de pago.\nCitation Format: Huyen TNT, Pumtong S, Sanroongruangsri S, Anuratpanich L (2022) Acceptability of and willingness to pay for human immunodeficiency virus vaccination: A systematic literature review. J Pharm Pharmacogn Res 10(4): 748\u2013767.\n[https://doi.org/10.56499/jppres22.1404_10.4.748]\nReferences\nAtujuna M, Newman PA, Wallace M, Eluhu M, Rubincam C, Brown B, Bekker LG (2018) Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: A qualitative study. PLOS ONE 13: e0191251.\nBakari M, Munseri P, Francis J, Aris E, Moshiro C, Siyame D, Janabi M, Ngatoluwa M, Aboud S, Lyamuya E (2013) Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania-the phase I/II HIVIS 03 trial. BMC Public Health 13: 1149.\nBarrington C, Moreno L, Kerrigan D (2007) Local understanding of an HIV vaccine and its relationship with HIV-related stigma in the Dominican Republic. AIDS Care 19: 871-877.\nBarrington C, Moreno L, Kerrigan D (2008) Perceived influence of an HIV vaccine on sexual\u2010risk behaviour in the Dominican Republic. Cult Health Sex 10: 391-401.\nBoardman AE, Greenberg DH, Vining AR, Weimer DL (2017) Cost-benefit analysis: concepts and practice, 4th edn. Cambridge, UK: Cambridge University Press.\nCameron MP, Newman PA, Roungprakhon S, Scarpa R (2013) The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine 31: 3712-3717.\nCook J, Jeuland M, Maskery B, Lauria D, Sur D, Clemens J, Whittington D (2009) Using private demand studies to calculate socially optimal vaccine subsidies in developing countries. J Policy Anal Manage 28: 6-28.\nCrosby RA, Holtgrave DR, Bryant L, Frew PM (2004) Correlates of negative intent to receive an AIDS vaccine: An exploratory study. Int J STD AIDS 15: 552-557.\nDhalla S, Poole G (2011) Motivators of enrolment in HIV vaccine trials: A review of HIV vaccine preparedness studies. AIDS Care 23: 1430-1447.\nDimi S, Zucman D, Chassany O, Lalanne C, Prazuck T, Mortier E, Majerholc C, Aubin-Auger I, Verger P, Duracinsky M (2019) Patients\u2019 high acceptability of a future therapeutic HIV vaccine in France: A French paradox? BMC Infect Dis 19: 401.\nDoshi M, Avery L, Kaddu RP, Gichuhi M, Gakii G, Du Plessis E, Dutta S, Khan S, Kimani J, Lorway RR (2017) Contextualizing willingness to participate: Recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials. BMC Public Health 17: 469.\nDrummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes, 4th edn. Oxford, UK: Oxford University Press.\nFrew PM, Crosby RA, Salazar LF, Gallinot LP, Bryant LO, Holtgrave DR (2008) Acceptance of a potential HIV/AIDS vaccine among minority women. J Natl Med Assoc 100: 802-816.\nHom D, Johnson J, Mugyenyi P, Byaruhanga R, Kityo C, Louglin A, Svilar G, Vjecha M, Mugerwa R, Ellner J (1997) HIV-1 risk and vaccine acceptability in the Ugandan military. J Acquir Immune Defic Syndr 15: 375-380.\nKakinami L, Newman PA, Lee SJ, Duan N (2008) Differences in HIV vaccine acceptability between genders. AIDS Care 20: 542-546.\nKeyserlingk CV, Rhodes B (2007) Using contingent valuation in hypothetical settings: Estimating the WTP for an HIV/AIDS vaccine. J Interdiscip Econ 18: 71-89.\nKim SY, Sagiraju H, Russell LB, Sinha A (2014) Willingness-to-pay for vaccines in low-and middle-income countries: A systematic review. Ann Vaccines Immunization 1: 1001.\nKoniak D, Nyamathi A, Tallen L, Gonz\u00e1lez-Figueroa E, Dominick E (2007) Breaking the silence: What homeless 18-to 24-year-olds say about HIV vaccine trials. J Health Care Poor Underserved 18: 687-698.\nKontomanolis EN, Michalopoulos S, Gkasdaris G, Fasoulakis Z (2017) The social stigma of HIV-AIDS: Society\u2019s role. HIV AIDS 9: 111-118.\nKpanake L, Gbandey S, Sorum PC, Mullet E (2018) Acceptability of vaccination against HIV: A mapping of Togolese people\u2019s positions. J H Psychol 23: 800-806.\nLally M, Gaitanis M, Vallabhaneni S, Reinert S, Mayer K, Zimet G, Rich J (2006) Willingness to receive an HIV vaccine among incarcerated persons. Prev Med 43: 402-405.\nLee SJ, Brooks RA, Newman PA, Seiden D, Sangthong R, Duan N (2008) HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care 20: 1161-1168.\nLee SJ, Newman PA, Duan N, Cunningham WE (2014) Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES. Vaccine 32: 5013-5018.\nLee S, Newman P, Comulada W, Cunningham W, Duan N (2012) Use of conjoint analysis to assess HIV vaccine acceptability: Feasibility of an innovation in the assessment of consumer health-care preferences. Int J STD AIDS 23: 235-241.\nLiau A, Zimet GD, Fortenberry JD (1998) Attitudes about human immunodeficiency virus immunization: The influence of health beliefs and vaccine characteristics. Sex Transm Dis 25: 76-81.\nLindegger G, Quayle M, Ndlovu M (2007) Local knowledge and experiences of vaccination: Implications for HIV-preventive vaccine trials in South Africa. Health Educ Behav 34: 108-123.\nMays RM, Zimet GD (2004) Recommending STI vaccination to parents of adolescents: The attitudes of nurse practitioners. Sex Transm Dis 31: 428-432.\nNewman P, Woodford M, Logie C (2012a) HIV vaccine acceptability and culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada. Glob Public Health 7: 87-100.\nNewman PA, Duan N, Lee SJ, Rudy ET, Seiden DS, Kakinami L, Cunningham WE (2006) HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics. Vaccine 24: 2094-2101.\nNewman PA, Lee SJ, Duan N, Rudy E, Nakazono TK, Boscardin J, Kakinami L, Shoptaw S, Diamant A, Cunningham WE (2009) Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high\u2010risk adults in Los Angeles (L.A. VOICES). Health Serv Res 44: 2167-2179.\nNewman PA, Logie C (2010) HIV vaccine acceptability: a systematic review and meta-analysis. Aids 24: 1749-1756.\nNewman PA, Roungprakhon S, Tepjan S, Yim S (2010) Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 28: 958-964.\nNewman PA, Roungprakhon S, Tepjan S, Yim S, Walisser R (2012b) A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand. Glob Public Health 7: 1009-1024.\nNguyen F (2007) Gauging the acceptability of HIV vaccines: An exploratory study examining knowledge, attitudes, and beliefs among injecting drug users in Viet Nam. J Ethn Cult Divers Soc Work 16: 161-192.\nNodin N, Carballo-Dieguez A, Ventuneac AM, Balan IC, Remien R (2008) Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care 20: 106-115.\nPage MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews BMJ 372: n71.\nPainter J, Cene-Kush C, Conner A, Cwiak C, Haddad L, Mulligan M, Diclemente R (2013) Anticipated HIV vaccine acceptability among sexually active African-American adult women. Vaccines 1: 88-104.\nRavert RD, Zimet GD (2009) College student invulnerability beliefs and HIV vaccine acceptability. Am J Health Behav 33: 391-399.\nRoberts KJ, Newman PA, Duan N, Rudy ET (2005) HIV vaccine knowledge and beliefs among communities at elevated risk: Conspiracies, questions and confusion. J Natl Med Assoc 97: 1662.\nRudy ET, Newman PA, Duan N, Kelly EM, Roberts KJ, Seiden DS (2005) HIV vaccine acceptability among women at risk: Perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev 17: 253-267.\nSalazar LF, Holtgrave D, Crosby RA, Frew P, Peterson JL (2005) Issues related to gay and bisexual men\u2019s acceptance of a future AIDS vaccine. Int J STD AIDS 16: 546-548.\nSayles JN, Macphail CL, Newman PA, Cunningham WE (2010) Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav 37: 193-210.\nSuraratdecha C, Hecht R (2005) Demand for a Preventive HIV Vaccine: A Review of the Literature. International AIDS Vaccine Initiative. Policy Research Working Paper # 3; pp. 39.\nThabethe S, Slack C, Lindegger G, Wilkinson A, Wassenaar D, Kerr P, Bekker LG, Mngadi K, Newman PA (2018) \u201cWhy don\u2019t you go into suburbs? Why are you targeting us?\u201d: Trust and mistrust in HIV vaccine trials in South Africa. J Empir Res Hum Res Ethics 13: 525-536.\nTremouillaux-Guiller J, Moustafa K, Hefferon K, Gaobotse G, Makhzoum A (2020) Plant-made HIV vaccines and potential candidates. Current Opinion in Biotechnology 61: 209-216.\nTsekoa TL, Singh AA, Buthelezi SG (2020) Molecular farming for therapies and vaccines in Africa. Curr Opin Biotechnol 61: 89-95.\nWeaver J, Newman PA, Williams CC, Massaquoi N, Brown M (2013) \u201cSisters, Mothers, Daughters and Aunties\u201d: HIV vaccine acceptability among African, Caribbean and other Black women in Toronto. Can J Public Health 104: e413-e417.\nWhittington D, Suraratdecha C, Poulos C, Ainsworth M, Prabhu V, Tangcharoensathien V (2008) Household demand for preventive HIV/AIDS vaccines in Thailand: Do husbands\u2019 and wives\u2019 preferences differ? Value Health 11: 965-974.\nYoung AM, Diclemente RJ, Halgin DS, Sterk CE, Havens JR (2014) HIV vaccine acceptability among high-risk drug users in Appalachia: A cross-sectional study. BMC Public Health 14: 537.\nZimet GD, Perkins SM, Sturm LA, Bair RM, Juliar BE, Mays RM (2005) Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 37: 179-186.\n\u00a9 2022 Journal of Pharmacy & Pharmacognosy Research (JPPRes)", "language": null, "image": null, "pagetype": "collectionpage", "links": ["https://jppres.com/jppres/", "#content", "https://jppres.com/jppres/home/", "https://jppres.com/jppres/inicio/", "https://jppres.com/jppres/about/", "https://jppres.com/jppres/acerca-de/", "https://jppres.com/jppres/archive/", "https://jppres.com/jppres/archive-2023/", "https://jppres.com/jppres/volume-11-issue-1/", "https://jppres.com/jppres/archive-2022/", "https://jppres.com/jppres/volume-10-issue-6/", "https://jppres.com/jppres/volume-10-issue-5/", "https://jppres.com/jppres/volume-10-issue-4/", "https://jppres.com/jppres/volume-10-issue-3/", "https://jppres.com/jppres/volume-10-issue-2/", "https://jppres.com/jppres/volume-10-issue-1/", "https://jppres.com/jppres/archive-2021/", "https://jppres.com/jppres/volume-9-issue-6/", "https://jppres.com/jppres/volume-9-suppl-1-micps-2021/", "https://jppres.com/jppres/volume-9-issue-5/", "https://jppres.com/jppres/volume-9-issue-4/", "https://jppres.com/jppres/volume-9-issue-3/", "https://jppres.com/jppres/volume-9-issue-2/", "https://jppres.com/jppres/volume-9-issue-1/", "https://jppres.com/jppres/archive-2020/", "https://jppres.com/jppres/volume-8-issue-6/", "https://jppres.com/jppres/volume-8-issue-5/", "https://jppres.com/jppres/volume-8-issue-4/", "https://jppres.com/jppres/volume-8-issue-3/", "https://jppres.com/jppres/volume-8-issue-2/", "https://jppres.com/jppres/volume-8-issue-1/", "https://jppres.com/jppres/archive-2019/", "https://jppres.com/jppres/volume-7-suppl-2-latinfarma-2019/", "https://jppres.com/jppres/volume-7-issue-6/", "https://jppres.com/jppres/volume-7-suppl-1-ztipc-2019/", "https://jppres.com/jppres/volume-7-issue-5/", "https://jppres.com/jppres/volume-7-issue-4/", "https://jppres.com/jppres/volume-7-issue-3/", "https://jppres.com/jppres/volume-7-issue-2/", "https://jppres.com/jppres/volume-7-issue-1/", "https://jppres.com/jppres/archive-2018/", "https://jppres.com/jppres/volume-6-issue-6/", "https://jppres.com/jppres/volume-6-issue-5/", "https://jppres.com/jppres/volume-6-issue-4/", "https://jppres.com/jppres/volume-6-issue-3/", "https://jppres.com/jppres/volume-6-issue-2/", "https://jppres.com/jppres/volume-6-issue-1/", "https://jppres.com/jppres/archive-2017/", "https://jppres.com/jppres/volume-5-issue-6/", "https://jppres.com/jppres/volume-5-issue-5/", "https://jppres.com/jppres/volume-5-issue-4/", "https://jppres.com/jppres/volume-5-issue-3/", "https://jppres.com/jppres/volume-5-issue-2/", "https://jppres.com/jppres/volume-5-issue-1/", "https://jppres.com/jppres/archive-2016/", "https://jppres.com/jppres/volume-4-issue-6/", "https://jppres.com/jppres/volume-4-issue-5/", "https://jppres.com/jppres/volume-4-issue-4/", "https://jppres.com/jppres/volume-4-issue-3/", "https://jppres.com/jppres/volume-4-issue-2/", "https://jppres.com/jppres/volume-4-issue-1/", "https://jppres.com/jppres/archive-2015/", "https://jppres.com/jppres/volume-3-issue-6/", "https://jppres.com/jppres/volume-3-issue-5/", "https://jppres.com/jppres/volume-3-suppl-1-fapronatura-2015/", "https://jppres.com/jppres/volume-3-issue-4/", "https://jppres.com/jppres/volume-3-issue-3/", "https://jppres.com/jppres/volume-3-issue-2/", "https://jppres.com/jppres/volume-3-issue-1/", "https://jppres.com/jppres/archive-2014/", "https://jppres.com/jppres/volume-2-issue-6/", "https://jppres.com/jppres/volume-2-issue-5-in-progress/", "https://jppres.com/jppres/volume-2-issue-4-in-progress/", "https://jppres.com/jppres/volume-2-issue-3/", "https://jppres.com/jppres/volume-2-suppl-1-latinfarma-2013/", "https://jppres.com/jppres/volume-2-issue-2/", "https://jppres.com/jppres/volume-2-issue-1/", "https://jppres.com/jppres/archive-2013/", "https://jppres.com/jppres/volume-1-issue-2/", "https://jppres.com/jppres/archive/volume-1-issue-1/", "https://jppres.com/jppres/authors/", "https://jppres.com/jppres/autores/", "https://jppres.com/jppres/submit-article/", "https://jppres.com/jppres/presentar-manuscrito/", "https://jppres.com/jppres/call-for-papers/", "https://jppres.com/jppres/reviewers/", "https://jppres.com/jppres/editorial-board/", "https://jppres.com/jppres/contact/", "http://jppres.wordpress.com/", "https://jppres.com/jppres/espanol-2/", "https://jppres.com/jppres/review-on-acceptability-and-wtp-for-hiv-vaccine/", "https://jppres.com/jppres/review-on-acceptability-and-wtp-for-hiv-vaccine/", "https://jppres.com/jppres/category/pharmaceutical-science/", "https://jppres.com/jppres/tag/acceptability/", "https://jppres.com/jppres/tag/article/", "https://jppres.com/jppres/tag/hiv/", "https://jppres.com/jppres/tag/immunization/", "https://jppres.com/jppres/tag/systematic-review/", "https://jppres.com/jppres/tag/vaccination/", "https://jppres.com/jppres/tag/willingness-to-pay/", "https://jppres.com/jppres/author/admin/", "https://doi.org/10.56499/jppres22.1404_10.4.748", "mailto:luerat.anu@mahidol.ac.th", "https://jppres.com/jppres/pdf/vol10/jppres22.1404_10.4.748.pdf", "https://jppres.com/jppres/pdf/vol10/jppres22.1404_10.4.748.pdf", "https://jppres.com/jppres/pdf/vol10/jppres22.1404_10.4.748.pdf", "https://doi.org/10.56499/jppres22.1404_10.4.748", "https://jppres.com/jppres/jppres-about/", "https://wordpress.org/"]}